Does the PI3K pathway promote or antagonize regulatory T cell development and function? by Dalya R. Soond et al.
REVIEW ARTICLE
published: 14         August 2012
doi: 10.3389/fimmu.2012.00244
Does the PI3K pathway promote or antagonize regulatory
T cell development and function?
Dalya R. Soond1, Elizabeth C. M. Slack1,2, Oliver A. Garden2, Daniel T. Patton3 and Klaus Okkenhaug1*
1 Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, UK
2 Regulatory T Cell Laboratory, Infection and Immunity Research Group, Department of Veterinary Clinical Sciences, The Royal Veterinary College,
Camden Campus, London, UK
3 Department of Microbiology and Immunology, Life Sciences Institute, The University of British Columbia, Vancouver, BC, Canada
Edited by:
Michael R. Gold, The University of
British Columbia, Canada
Reviewed by:
Ciriaco A. Piccirillo, McGill University
and Research Institute of the McGill
University Health Center, Canada
Laurence Turka, Beth Israel
Deaconess Medical Center, USA
*Correspondence:
Klaus Okkenhaug, Laboratory of
Lymphocyte Signalling and
Development, Babraham Institute,
Cambridge, CB22 3AT, UK.
e-mail: klaus.okkenhaug@
babraham.ac.uk
Regulatory T cells (Tregs) prevent autoimmunity and inflammation by suppressing the
activation of other T cells and antigen presenting cells. The role of phosphoinositide
3-kinase (PI3K) signaling in Treg is controversial. Some studies suggest that inhibition of
the PI3K pathway is essential for the development of Tregs whereas other studies have
shown reduced Treg numbers and function when PI3K activity is suppressed. Here we
attempt to reconcile the different studies that have explored PI3K and the downstream
effectors Akt, Foxo, and mTOR in regulatory T cell development and function and discuss
the implications for health and therapeutic intervention.
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INTRODUCTION
The class I phosphoinositide 3-kinases (PI3Ks) consist of het-
erodimers between one regulatory and one catalytic subunit.
The Class IA catalytic subunit isoforms (p110α, p110β, and
p110δ) can be activated by tyrosine kinase-associated and some-
times G protein-coupled receptors while the Class IB isoform
(p110γ) can only be activated by G protein-coupled receptors.
Each class I PI3K isoform uses PtdIns(4,5)P2 as its preferred
substrate to generate the second messenger PtdIns(3,4,5)P3,
which helps activate PH domain-containing signaling proteins.
Key downstream targets include Akt, PDK-1, and Tec fam-
ily kinases (Okkenhaug and Fruman, 2010; So and Fruman,
2012).
PtdIns(3,4,5)P3 generation recruits and co-localizes Akt and
PDK1 to the plasma membrane. PDK1 can then phosphorylate
Akt on Thr308. A second phosphorylation at Ser473 is required
for optimal Akt activity. This residue is phosphorylated by the
rapamycin-insensitive mTOR/Rictor complex (mTORC2) and
de-phosphorylated by PHLPP. Akt, together with numerous other
upstream regulators, can then indirectly contribute to activation
of the rapamycin-sensitive mTOR/Raptor complex (mTORC1).
Akt also phosphorylates the transcription factor FOXO, which
leads to its exclusion from the nucleus, thus altering T cell home-
ostasis and trafficking (Kerdiles et al., 2009; Finlay and Cantrell,
2010).
PtdIns(3,4,5)P3 signaling is terminated by two classes of
phosphatases. Pten dephosphorylates PtdIns(3,4,5)P3 on the
D3 position to maintain resting levels of PtdIns(4,5)P2. SHIP
phosphatases dephosphorylate PtdIns(3,4,5)P3 on the D5 posi-
tion to generate PtdIns(3,4)P2, which has signaling properties
of its own (Okkenhaug and Fruman, 2010; So and Fruman,
2012).
The PI3K isoform p110δ was shown to be the dominant iso-
form downstream of the T cell receptor (TCR), the co-stimulatory
receptor ICOS, and the IL-2 receptor (Okkenhaug et al., 2002,
2006; Rolf et al., 2010; Soond et al., 2010; Macintyre et al., 2011).
Consequently, p110δ controlled proliferation, cytokine produc-
tion, differentiation into helper T cells (Th) subsets, and traffick-
ing (Okkenhaug et al., 2002, 2006; Nashed et al., 2007; Garcon
et al., 2008; Jarmin et al., 2008; Sinclair et al., 2008; Liu et al., 2009;
Rolf et al., 2010; Soond et al., 2010; Macintyre et al., 2011). The
p110γ isoform of PI3K is required for migration toward inflam-
matory chemokines and memory T cell survival (Barber et al.,
2006; Martin et al., 2008; Thomas et al., 2008). Conversely, T cells
lacking Pten are hypersensitive to TCR and IL-2 signaling lead-
ing to augmented Th cell functions, autoimmunity, and leukemia
(Suzuki et al., 2001; Buckler et al., 2006; Liu et al., 2010; Guo et al.,
2011; Soond et al., 2012).
The role of the PI3K pathway in T cells has been addressed
experimentally by either inhibiting PI3K signaling (e.g. by inacti-
vating PI3K or downstream proteins such as PDK1 or mTOR) or
by increasing PI3K signaling (e.g. by deleting Pten, SHIP or Foxo,
or by overexpressing membrane-targeted Akt). Although there
seems to be a clear positive role for the PI3K pathway in inducing
the activation, differentiation, and maintenance of Th cells, data
regarding its precise effect in regulatory T cells (Tregs) appears
contradictory. In this review, we will briefly summarize what is
known about the development and function of Tregs, describe
how Tregs are regulated by the PI3K pathway, and propose how
conflicting data can be reconciled.
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Tregs SUPPRESS IMMUNE RESPONSES
Tregs are defined as the 5–10% of CD4+ T cells that express the
transcription factor Foxp3. Foxp3 expression is both necessary
and sufficient to confer suppressive ability to Tregs. Tregs pre-
vent autoimmunity, restrain the responses to infectious agents,
aid maternal tolerance toward fetuses and block tumor immu-
nity. Their importance has been shown in cases where Foxp3 is
lost or attenuated such as IPEX syndrome in humans or scurfy
mice, where by multi-organ autoimmunity and inflammation
rapidly develops, leading to death of the organism (Bennett et al.,
2001; Brunkow et al., 2001; Wildin et al., 2001; Yamaguchi et al.,
2011; Josefowicz et al., 2012a). Depletion of Foxp3+ cells in adult
mice also leads to fatal disease, highlighting their role in prevent-
ing responses throughout the life of the organism (Kim et al.,
2007).
Treg DEVELOP IN THE THYMUS AND PERIPHERY
The majority of Treg cells are generated in the thymus and are
termed “natural Tregs” (nTregs). Commitment to this lineage
occurs in two steps. First, TCR signaling in CD4+CD8+ dou-
ble positive T cells poises them to express Foxp3, which then
occurs in a second IL-2-dependent but TCR-independent step
(Lio and Hsieh, 2008). The amount of TCR signaling required
for the positive selection of Tregs is higher than for conventional
T cells, but less than is required for negative selection. Hence,
the TCRs expressed by Tregs tend to have higher affinity for self-
peptide/MHC complexes than those expressed by Th cells (Hsieh
et al., 2012).
Tregs can also be generated outside the thymus from naïve
CD4+ T cells. These “induced Tregs” (iTregs) develop when
the TCR is activated under immunosuppressive conditions
in the presence of TGFβ1 (Chen et al., 2003), indoleamine
2,3-dioxygenase, or other amino acid metabolizing enzymes
(Chen et al., 2008; Chung et al., 2009; Cobbold et al., 2009), or
when T cells are activated by Ag at low doses or low affinity anti-
gen (Daniel et al., 2010; Gottschalk et al., 2010). Although there
is a lack of reliable markers to unequivocally track the survival of
iTreg, it is estimated that iTreg represent only a small proportion
of the total Treg population under homeostatic conditions (Zheng
et al., 2010; Josefowicz et al., 2012b).
The Foxp3 gene locus contains a promoter and three addi-
tional conserved non-coding DNA sequences (CNS1-3) which
include binding sites for diverse transcription factors such as
NFAT, NF-κB, AP1, STAT5, Cbf, Runx, Foxo, Foxp3, SMAD, and
other factors (Merkenschlager and Von Boehmer, 2010; Zheng
et al., 2010). The number of elements involved in Foxp3 regula-
tion suggests this locus is tightly controlled and highly responsive
to context-dependent cues. Not all of these transcription factors
or promoter regions are required for Foxp3 transcription at all
times. CNS3, which binds c-Rel but not other members of the
NF-κB transcription factor family, is considered to be a pioneer
element accessible in Treg precursors. Consistent with this, Treg
development in the thymus is blocked in the absence of CNS3
or c-Rel (Isomura et al., 2009; Visekruna et al., 2010; Zheng
et al., 2010). The CNS1 element binds Smad3 and—along with
CNS3—is required for TGF-β-induced conversion to iTreg. CNS1
deficiency primarily affects Treg numbers at environmentally
exposed tissues such as the intestine and lung where iTregs are
most frequently found, but is dispensable for nTreg development
(Zheng et al., 2010; Josefowicz et al., 2012b). CNS2, but not CNS3,
is required for maintenance of Treg in the periphery (Zheng et al.,
2010). This is of interest as CNS2 binds Foxp3 protein and may
hence stabilize the lineage as part of a positive feedback loop.
Multiple regulatory inputs mean that a genetic lesion may alter
Treg numbers by affecting the development and/or maintenance
of Foxp3.
Fate-mapping studies have shown somewhat conflicting
results with regards to Treg plasticity.While some studies had sug-
gested that some Treg can be re-differentiated to other Th lineages
(Tsuji et al., 2009; Zhou et al., 2009), further studies suggest that
the expression of Foxp3 is highly stable and irreversible (Rubtsov
et al., 2010; Miyao et al., 2012). However, it is possible that a
certain percentage of Th cells express Foxp3 transiently, but sub-
sequently are diverted to other lineages (Komatsu et al., 2009).
Consistent with this notion, when expression of Foxp3 was inten-
tionally destabilized, the Foxp3low T cells were subverted into Th2
cells that caused disease (Wan and Flavell, 2007). It should be
noted however, that fully committed Foxp3+ Treg can co-express
transcription factors associated with other T cells lineages, such
as Tbet, Gata3, IRF4, or Bcl6. This may help adapt the Foxp3+
Treg to limit particular types of immune responses, for instance
by targeting them to the correct anatomical location (Josefowicz
et al., 2012a).
PI3K ACTIVITY SUPRESSES THE DEVELOPMENT OF nTreg
How does the PI3K pathway affect development of nTregs in
the thymus? The p110δD910A mouse, in which p110δ is inacti-
vated by point mutation, showed increased proportions of Tregs
in the thymus (Patton et al., 2006). There were more immature
as well as mature thymic Tregs, suggesting that the increased
Foxp3+ population reflects enhanced development of Foxp3+
T cells rather than accumulation of mature Treg that fail to emi-
grate to the periphery (Patton et al., 2006). Consistent with a
negative role for PI3K in nTreg development, retroviral expres-
sion of oncogenic Akt reduced the number of nTregs (Haxhinasto
et al., 2008). Treg numbers were also dramatically decreased in
the thymi of mice lacking Foxo1 and Foxo3 expression in T cells,
although this defect resolved as the mice aged (Kerdiles et al.,
2010; Ouyang et al., 2010). Foxo transcription factors have been
found to directly bindCNS1 andCNS3 regions of the Foxp3 locus,
providing a direct mechanism for their role in nTreg and iTreg
development (Harada et al., 2010; Ouyang et al., 2010). By con-
trast, in mice lacking mTOR in T cells there was no difference in
nTreg (Delgoffe et al., 2009). The simplest conclusion from these
experiments is that the PI3K p110δ antagonizes nTreg develop-
ment by activating Akt, leading to the exclusion of Foxo from the
nucleus.
In apparent contradiction to these results, mice lacking PDK1
in T cells had reduced Treg numbers in the thymus (Park et al.,
2010). It is important to appreciate, however, that PDK1 regulates
multiple protein kinase C isoforms independently of PI3K and
Akt (Mcmanus et al., 2004; Waugh et al., 2009); hence the reduced
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numbers of thymic Treg in these mice might be a consequence of
impaired c-Rel activation (which depends on PKC activity) rather
than interrupted PI3K signaling.
PI3K SIGNALS CAN ENHANCE OR BLOCK PERIPHERAL
CONVERSION OF NAÏVE CD4+ T CELLS
We found that TGF-β1-stimulated iTreg conversion was reduced
when we used the pan-PI3K inhibitor PI-103, the p110δ-selective
inhibitor IC87114 or rapamycin (Patton et al., 2011); however,
others have observed enhanced iTreg conversion upon addition
of PI3K or mTOR inhibitors (Harada et al., 2010; Patterson et al.,
2011). We do not have an explanation for these differences other
than it may depend on the amount of costimulation provided
in the conversion cultures, as in some cases CD28 signals can
compensate for the lack of PI3K activity in T cells (Okkenhaug
et al., 2002; Garcon et al., 2008; Gogishvili et al., 2008). PDK1−/−
T cells showed reduced conversion to iTreg in vitro and in vivo
(Park et al., 2010) while more iTregs developed upon stable trans-
genic expression of active Akt (Pierau et al., 2009). These latter
studies suggest that PI3K pathway activation is required for iTreg
differentiation, possibly at the level of initial activation, stabiliza-
tion of Foxp3 expression, or survival of Foxp3+ cells. However,
TGF-β-dependent conversion was reduced upon deletion of Pten,
PHLPP or Foxo transcription factors, or by retroviral expression
of Akt (Haxhinasto et al., 2008; Sauer et al., 2008; Patterson et al.,
2011). Therefore, very high PI3K-Akt activity may be incompati-
ble with iTreg conversion, presumably because it would eliminate
Foxo from the nucleus.
Foxp3 expression also can be induced in naïve CD4+ T cells
independently of TGF-β1 by removing cells from TCR stim-
uli 18 h after initial activation in vitro (Sauer et al., 2008).
Interestingly, this effect could be enhanced by the addition of
PI3K andmTOR inhibitors also added 18 h after activation (Sauer
et al., 2008). TCR deprivation could not induce Foxp3 expression
in Foxo1−/−Foxo3−/− T cells, suggesting that the effect of the
PI3K inhibitors depends on nuclear expression of Foxo (Ouyang
et al., 2010).
PI3K AND mTOR INHIBITION HAVE OPPOSING EFFECTS
ON PERIPHERAL Treg HOMEOSTASIS AND EXPANSION
Once Foxp3 is expressed, Tregs must process external cues in
order to be maintained. One indicator of intact maintenance is
the preservation of normal levels of Tregs under homeostatic con-
ditions. There were 2-fold fewer peripheral Tregs in p110δD910A
mice despite increased nTreg generation (Patton et al., 2006). This
implies that PI3K signals are important for maintenance of Tregs.
Consistent with this, Pten−/− Treg show enhanced proliferation
in response to IL-2 and mice in which Pten was deleted in Treg
(as well as activated CD4+ T cells) have increased numbers of
peripheral Treg (Walsh et al., 2006; Soond et al., 2012). Although
Tregs with inactive p110δ proliferated normally in responses to
IL-2 in vitro (Patton et al., 2006), it is possible that integrated sig-
nals from the TCR and IL-2R fail to support normal Treg numbers
in p110δD910A mice in vivo. Mice with Foxo1 and Foxo3 deleted
in T cells show a gradual recovery of Treg numbers with age,
suggesting that Foxo may play a more important role in initial
development of Tregs than in their maintenance in the periphery
(Kerdiles et al., 2010).
Deprivation of mTOR signals by rapamycin or by deleting
the gene encoding the mTOR catalytic subunit in T cells favors
the expansion of Tregs (Battaglia et al., 2005; Delgoffe et al.,
2009). Immunization with very low peptide concentrations pro-
motes Treg differentiation and this is enhanced by rapamycin
(Daniel et al., 2010).Whether mTOR inhibition actually enhances
Treg expansion or gives Treg a selective growth advantage over
other Th cell lineages remains a subject of debate. In a fur-
ther twist, a recent study has also shown reduced expansion
of Foxp3− T cells after transfer of Foxp3+ T cells into lym-
phopenic hosts (Yurchenko et al., 2012). Whether this represented
true reprogramming or these apparently converted Foxp3− T
cells were derived from contaminating Foxp3− progenitors or
partially differentiated Foxp3+ cells could not be established
conclusively.
There are a number of potential mechanisms that render
Treg insensitive, or even activated, by mTOR inhibition. Tregs
express high levels of the serine-threonine kinase Pim2, which
shares many targets in common with mTOR (Basu et al., 2008).
Prolonged treatment with rapamycin can partially inhibit phos-
phorylation of Akt and hence enhance nuclear retention of Foxo
(Sarbassov et al., 2006). Rapamycin can also mimic the effect of
amino acid deprivation which favors Treg expansion (Cobbold
et al., 2009). Furthermore, in contrast to Th, Tregs depend highly
on lipid oxidation rather than glycolysis. By inhibiting mTOR-
dependent glycolysis in favor of lipid oxidation, rapamycin may
favor the expansion of Tregs (Michalek et al., 2011; Shi et al.,
2011).
Tregs HAVE MANY MECHANISMS TO SUPPRESS
IMMUNE RESPONSES
Perhaps more important than the role in the development and
maintenance is the question of whether PI3K signaling controls
Treg-mediated suppression. Tregs provide a dominant mech-
anism of peripheral tolerance and hence moderate variations
in their absolute numbers do not necessarily have significant
impacts on their ability to prevent disease. Rather, it is the amount
of Foxp3 expressed per Treg that is essential (Wan and Flavell,
2007).
Tregs employ a variety of mechanisms to suppress the immune
system, and these differ whether the Tregs are suppressing
immune responses elicited by self-antigens or commensal bac-
teria (Yamaguchi et al., 2011). Tregs can secrete suppressive
cytokines such as IL-10, TGF-β, and IL-35 (Read et al., 2000;
Collison et al., 2007; Rubtsov et al., 2008) which directly inhibit
T cells and accessory leukocytes. IL-10 is critical in the gut, as
mice with a Treg-specific deficiency in IL-10 develop inflam-
matory bowel disease, but not systemic autoimmunity (Rubtsov
et al., 2008). Tregs constitutively express high levels of the IL-2R,
and they can deprive conventional T cells of access to IL-2
(Pandiyan et al., 2007, 2011). CTLA-4 is also essential for Treg
suppression, as Treg-specific CTLA-4 knockout mice succumb
to a severe autoimmune syndrome (Wing et al., 2008). CTLA-4
blocks T cell activation by physically removing CD80 and CD86
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FIGURE 1 | Context-dependent effect of PI3K signaling on Treg
development, differentiation and maintenance. (A) During thymic
development, attenuation of PI3K signaling may be required to enhance the
translocation of Foxo proteins to the nucleus where they enhance the
expression of Foxp3. (B) The capacity of PI3K signaling to antagonize is
illustrated during the in vitro differentiation of Foxp3− CD4 T cells to Foxp3+
T cells where signal attenuation after 18h facilitates Foxo nuclear
translocation. It is worth noting that earlier inhibition may interfere with
TCR-dependent signals that favor Foxp3 expression. (C) Hyperactivation of
Akt (e.g. by expression of a membrane targeted Akt transgene) leads to Foxo
nuclear exclusion and reduced Foxp3 expression. Whether such extent of Akt
activation can be achieved by physiological receptor activation has yet to be
determined. (D) Treg numbers in the periphery is controlled by both TCR and
IL-2 signals. Inhibition of PI3K is likely to reduce the ability of these receptors
to maintain Treg homeostasis, thus explaining the reduced number of Treg in
p110δ-deficient mice. (E) Enhanced numbers of Treg are found upon deletion
of Pten or Ship in T cells in which PI3K signaling is enhanced, probably
reflecting enhanced IL-2-dependent homeostatic expansion.
Frontiers in Immunology | T Cell Biology August 2012 | Volume 3 | Article 244 | 4
+
Soond et al. PI3K and Treg
from dendritic cells, thus depriving effector T cells of costim-
ulation (Yokosuka et al., 2010; Qureshi et al., 2011). CTLA-4
binding can also instruct dendritic cells to release indoleamine
2,3-dioxygenase, which produces pro-apoptotic kyneurenines
and deprives proliferating T cells of the tryptophan needed for
growth (Grohmann et al., 2002). Tregs can transfer the inhibitory
second messenger cAMP via gap junctions (Bopp et al., 2007),
alter levels of extracellular nucleotides using CD38, CD39, and
CD73 (Chen et al., 2006; Deaglio et al., 2007; Hubert et al.,
2010), and kill activated leukocytes through the release of per-
forin or granzyme (Cao et al., 2007; Boissonnas et al., 2010).
However, no single mechanism has been identified which either
is unique to Tregs or which accounts for all aspects of Treg-
mediated suppression (Yamaguchi et al., 2011; Josefowicz et al.,
2012a).
PI3K PROMOTES Treg-MEDIATED SUPPRESSION
p110δD910A Tregs produce less IL-10 and show reduced suppres-
sion of CD4+ T cell proliferation in vitro (Patton et al., 2006,
2011). The reduced ability of p110δ-deficient Treg to supress was
correlated with lower expression of CD38, a marker of a highly
suppressive Treg population in the gut, suggesting that “effector”
Tregs may not develop normally in p110δD910A mice (Cretney
et al., 2011; Patton et al., 2011). Tregs from p110δD910A cannot
block the development of experimental colitis induced by trans-
fer of naïve T cells in Rag knockout mice (Patton et al., 2006).
Consistent with this, p110δD910A mice spontaneously develop col-
itis of similar severity to that observed in IL-10-deficient mice
(Okkenhaug et al., 2002; Uno et al., 2010). IL-10−/−p110δD910A
double deficient mice develop a more severe form of colitis
(Uno et al., 2010), suggesting that the disease caused by p110δ-
deficiency is not only a consequence of impaired IL-10 pro-
duction. PDK1−/− Tregs had multiple functional defects that
resulted in the failure to suppress γδ T cell-dependent colitis,
again suggesting a key role for PI3K signaling in suppression of
gut-associated inflammation (Park et al., 2010). Mice lacking p85
regulatory subunits in T cells develop Sjogrens syndrome, per-
haps also as a consequence of impaired Treg function, although
this mechanism was not examined directly (Oak et al., 2006). In
the context of infection, p110δD910A mice showed a surprising
increased ability to eliminate Leishmania parasites despite mount-
ing a reduced Th1 response. This was explained, at least in part,
by reduced Treg expansion and/or function in p110δD910A mice as
the transfer of Treg into p110δD910A mice reversed their resistance
to Leishmania (Liu et al., 2009). It should be noted that so far, no
evidence of autoimmunity has been described in PI3K-deficient
mice, suggesting that defective Treg function in these mice pri-
marily affect responses to commensal or pathogenic organisms.
Both SHIP−/− and Pten−/− Treg suppressed normally in vitro
and in vivo suggesting that moderately increased levels of PI3K
activity is compatible with normal Treg function (Kashiwada
et al., 2006; Walsh et al., 2006; Collazo et al., 2009; Locke
et al., 2009; Patterson et al., 2011; Soond et al., 2012). However,
Tregs overexpressing active Akt or in which the Akt-phosphatase
PHLPP were deleted showed reduced capacity to suppress CD4+
T cell proliferation (Crellin et al., 2007; Patterson et al., 2011).
Thus, some PI3K activity is required for optimal Treg-mediated
suppression, but very high Akt activity can inhibit Treg
suppression.
CONCLUSIONS
Does the PI3K pathway promote or antagonize regulatory T cell
development and function? The answer seems to be: both.
The findings that the Foxp3 gene contains Foxo-binding
elements in its promoter region, along with the observation
that PI3K inhibitors added 18 h after activation could be used
to induce Treg differentiation raised the possibility that PI3K
inhibitors could be used to enhance Treg induction in vivo (Bruno
and Merkenschlager, 2008; Ohkura et al., 2011). However, inhi-
bition of PI3K signaling in mice does not lead to increased
numbers of peripheral Treg, even when deleted after activa-
tion using OX40-Cre (Rolf et al., 2010). Moreover, the evidence
for enhanced Treg proportions or numbers in patients taking
rapamycin or its analogs is lacking, despite the demonstrated
property of rapamycin to favor the expansion of established Treg
in vitro and in vivo (Zuber et al., 2011). Figure 1 illustrates how
PI3K signaling can both antagonize and augment Treg numbers,
depending on the stage of differentiation, timing, and extent of
activation/inactivation.
The development of colitis and Sjogren’s syndrome in mice
with chronic inhibition of the PI3K pathway suggests that, on
balance, inhibition of PI3K is more likely to inhibit Treg func-
tion than enhance it. It is therefore unlikely that patients who
are administered p110δ-selective inhibitors would have enhanced
Treg function. Whether impairment in Treg function or home-
ostasis leading to a clinical manifestation will be a significant
detrimental side effect in patients who are administered PI3K
inhibitors is not yet clear; however, serious side effects have not
been reported in initial clinical trials so far (Furman et al., 2010;
Fruman and Rommel, 2011). Indeed, protective effects of p110δ
inhibition in mouse models of asthma, multiple sclerosis, arthri-
tis, and lupus suggest that blockade of effector T cells dominates
(Nashed et al., 2007; Durand et al., 2009; Haylock-Jacobs et al.,
2011). A number of pharmaceutical companies are also develop-
ing p110δ or p110γ inhibitors to treat leukemia or autoimmune
diseases (Fruman and Rommel, 2011; Norman, 2011; So and
Fruman, 2012). The first publically available results from clin-
ical trials using p110δ inhibitors suggest a remarkable response
rate in patients with chronic lymphocytic leukemia, nearly all of
whom showed reduced lymph node size after treatments in phase
I trials (Furman et al., 2010). Could inhibition of Treg by p110δ
inhibitors be exploited therapeutically? One positive outcome of
reduced Treg function was shown in p110δD910A mice which were
resistant to infection with Leishmania (Liu et al., 2009). A recent
study suggested a beneficial effect of PI3K inhibitors as adjuvants
to cancer vaccines (Marshall et al., 2012). We are currently explor-
ing whether p110δ-inhibition of Treg function could be used to
enhance anti-tumor responses. In summary, inhibiting PI3K can
facilitate the differentiation of Treg in vitro, but in vivo, the net
results of PI3K inhibition is fewer Tregs with reduced, but not
abolished, suppressive capacity.
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